“One thing that from the very beginning we talked about is how can we push this forward? How can we think outside the box and take this to the next level to make an impact for our patients?” says Katie Murray, DO, MS.
In this video, Katie Murray, DO, MS, and Kimberly Kocour, MD, share the take-home message from the South Central Section of the AUA Annual Meeting abstract, "Prostatic artery embolization: an option for select male patients with necessary collaboration between urology and interventional radiology." Murray is an assistant professor at the University of Missouri Division of Urology in Columbia. Kocour is a urology resident at the University of Missouri.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.